Data Provided by Refinitiv. Minimum 15 minutes delayed.

Immunovaccine Announces Changes to Stock Option Plan

October 6, 2014 at 12:00 AM EDT

Halifax, Nova Scotia; October 6, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV” or “the Company”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company, today announced that its board of directors has approved a modification to the Company’s stock option plan (the “Plan”).  Under this amendment, the Company will increase the number of common shares of the Company reserved for issuance under the Plan from 6,750,000 to 9,100,000.  The amendment to the Plan is pending approval by the TSX Venture Exchange. 

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer.  The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.  

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information.  Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.  However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Dr. Marc Mansour, Chief Executive Officer, Immunovaccine Inc.

T: (902) 492-1819   E:


Tim Brons, Vida Strategic Partners (media)

T: (415) 675-7402   E: